Ondine Biomedical (LON:OBI) Trading Down 7.9% – Time to Sell?

Shares of Ondine Biomedical Inc. (LON:OBI) dropped 7.9% during mid-day trading on Tuesday . The stock traded as low as C$12.00 and last traded at C$12.25. Approximately 53,936 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 429,282 shares. The stock had previously closed at C$13.30.

Ondine Biomedical Stock Performance

The firm has a market cap of C$3.40 billion, a price-to-earnings ratio of -408.33 and a beta of 0.10. The company has a debt-to-equity ratio of 1,847.37, a current ratio of 0.80 and a quick ratio of 8.26. The firm’s fifty day moving average is C$9.90 and its 200-day moving average is C$8.22.

Insider Activity at Ondine Biomedical

In other news, insider Carolyn Cross bought 149,225 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were acquired at an average price of C$13.00 per share, for a total transaction of C$1,939,925.00. 36.69% of the stock is owned by company insiders.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.